Stericyle stock rises as its purchase by Waste Management clears regulatory hurdles
By Steve Gelsi
Company's $7.2 billion deal with Waste Management OK'd by Federal Trade Commission
Medical-waste handler Stericycle Inc.'s stock was up 4.4% on Friday after the company said the Federal Trade Commission waiting period for its June 3 merger with Waste Management Inc. expired.
The deal for Stericycle (SRCL) also won antitrust clearance in the U.K. and Portugal.
Stericycle said it expects to complete the merger as early as the fourth quarter after it receives additional antitrust clearance in Canada and Spain.
Waste Management (WM) said in June it planned to pay $62 a share for Stericycle in a deal that values the Bannockburn, Ill.-based company at about $7.2 billion including debt.
Along with medical waste disposal, Stericycle also specializes in secure information destruction.
Stericycle was one of the more heavily-traded stocks in premarket action on Friday following its deal update disclosure after the closing bell on Thursday.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-06-24 0949ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks